[CYCC] Cyclacel Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.95 Change: -0.05 (-1.25%)
Ext. hours: Change: 0 (0%)

chart CYCC

Refresh chart

Strongest Trends Summary For CYCC

CYCC is in the medium-term down -31% in 2 months. In the long-term down -100% below S&P in 13 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company?s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatmen

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters2.06% EPS Growth - Q/Q2.33%
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.82% Sales Growth - Q/Q107.29% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-54.95% ROE-71.89% ROI
Current Ratio4.3 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin-1206.76% Net Profit Margin-1050.27% Dividend Payout Ratio1.03%
Dividend Yield
Fundamental Data
Cash From Financing Activities10.38 M Cash From Investing Activities10 K Cash From Operating Activities-4.9 M Gross Profit
Net Profit-4.91 M Operating Profit-5.3 M Total Assets35.36 M Total Current Assets35.02 M
Total Current Liabilities8.14 M Total Debt Total Liabilities8.33 M Total Revenue510 K
Technical Data
High 52 week1.64 Low 52 week0.56 Last close0.69 Last change0%
RSI45.82 Average true range0.04 Beta0.71 Volume60.16 K
Simple moving average 20 days-2.2% Simple moving average 50 days-12.8% Simple moving average 200 days-32.99%
Performance Data
Performance Week-0.71% Performance Month-4.17% Performance Quart-12.66% Performance Half-42.5%
Performance Year-49.26% Performance Year-to-date14.05% Volatility daily2.05% Volatility weekly4.58%
Volatility monthly9.39% Volatility yearly32.54% Relative Volume171.73% Average Volume755.71 K
New High New Low

News

2019-05-24 12:50:18 | A Look At Benzinga Pro's Most-Searched Tickers For May 24

2019-05-14 22:22:40 | Edited Transcript of CYCC earnings conference call or presentation 14-May-19 8:30pm GMT

2019-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2019 Financial Results

2019-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

2019-04-29 09:55:51 | Could Cyclacel Pharmaceuticals, Inc.'s NASDAQ:CYCC Investor Composition Influence The Stock Price?

2019-04-01 07:00:00 | Cyclacel Announces Presentation of Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

2019-03-28 08:16:49 | Edited Transcript of CYCC earnings conference call or presentation 27-Mar-19 8:30pm GMT

2019-03-27 16:05:00 | Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-03-27 07:52:54 | The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO

2019-03-26 12:46:27 | Cyclacel Drops After Study Supporting Cancer Drug's Mechanism Of Action

2019-03-26 08:30:00 | Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

2019-03-25 07:00:00 | Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors and Thereby Amenable to Treatment by CYC065 CDK2/9 Inhibitor

2019-03-20 07:00:00 | Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results

2019-03-13 07:00:00 | Cyclacel to Participate in 31st Annual ROTH Conference March 18-19

2019-03-05 07:00:00 | Cyclacel Announces Abstracts Selected for Presentation at the American Association for Cancer Research Annual Meeting 2019

2019-02-05 07:00:00 | Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference

2019-01-24 07:25:00 | New Research: Key Drivers of Growth for Square, American International Group, PolyOne, Sonoco Products, Enviva Partners, LP, and Cyclacel Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production

2019-01-07 07:00:00 | Cyclacel Pharmaceuticals Reviews 2018 Achievements and Announces Key Business Objectives for 2019

2018-12-27 07:00:00 | Cyclacel Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco

2018-12-25 14:25:20 | Does Cyclacel Pharmaceuticals, Inc.’s NASDAQ:CYCC CEO Pay Reflect Performance?

2018-12-04 07:35:00 | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage — Fundamental Analysis, Key Performance Indications

2018-11-13 07:54:38 | The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

2018-11-13 07:26:43 | Edited Transcript of CYCC earnings conference call or presentation 12-Nov-18 9:30pm GMT

2018-11-12 16:05:00 | Cyclacel Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-06 07:00:00 | Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results

2018-10-25 08:30:00 | Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-23 07:00:00 | Cyclacel Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

2018-10-04 07:00:00 | Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological Malignancies

2018-09-26 07:00:00 | Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-20 13:01:51 | What does Cyclacel Pharmaceuticals Inc’s NASDAQ:CYCC Balance Sheet Tell Us About Its Future?

2018-09-12 07:00:00 | Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors

2018-09-10 07:00:00 | Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

2018-09-05 07:30:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group — New Research Emphasizes Economic Growth

2018-08-29 07:00:00 | Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference

2018-08-23 17:45:25 | Edited Transcript of CYCC earnings conference call or presentation 9-Aug-18 8:30pm GMT

2018-08-16 08:15:00 | Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource — Discovering Underlying Factors of Influence

2018-08-09 16:05:00 | Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-09 14:30:00 | Cyclacel Pharmaceuticals, Inc. to Host Earnings Call

2018-08-01 07:00:00 | Cyclacel Pharmaceuticals to Release Second Quarter 2018 Financial Results

2018-05-25 14:09:18 | Who Really Owns Cyclacel Pharmaceuticals Inc NASDAQ:CYCC?

2018-05-21 17:23:42 | Edited Transcript of CYCC earnings conference call or presentation 14-May-18 8:30pm GMT

2018-05-14 16:05:00 | Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results

2018-05-14 12:30:00 | Cyclacel Pharmaceuticals, Inc. to Host Earnings Call

2018-05-14 10:51:14 | Cyclacel Pharmaceuticals Inc’s NASDAQ:CYCC Earnings Dropped -23.81%, Did Its Industry Show Weakness Too?

2018-05-08 07:00:00 | Cyclacel Pharmaceuticals to Release First Quarter 2018 Financial Results

2018-05-04 08:10:00 | Recent Analysis Shows Lancaster Colony, Calavo Growers, Acuity Brands, Cyclacel Pharmaceuticals, Enbridge Energy Management, and Nasdaq Market Influences — Renewed Outlook, Key Drivers of Growth

2018-04-17 09:00:00 | Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

2018-04-16 07:00:00 | Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

2018-04-13 11:38:23 | The Week Ahead In Biotech: PDUFA Dates, IPOs And More

2018-04-09 07:10:00 | Wired News – Stemline Therapeutics Initiates Rolling BLA Submission for SL-401